Guidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products
2017-08-14
FDA-2017-D-4713
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Guidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products August 2017
FDA Announces it is Reopening Comment Period on Use of Ultrafiltered Milk in Certain Cheeses
March 26, 2020
The FDA is reopening the comment period on the proposed rule to permit the use of ultrafiltered milk in certain cheeses and related cheese products to provide stakeholders an additional 120 days to submit comments. The current comment period will close on March 30, 2020; the new comment period will close 120 days following publication of the notice in the Federal Register. FDA will notify stakeholders when the Federal Register notice publishes.
I. Introduction
The purpose of this guidance is to advise manufacturers who wish to use ultrafiltered milk (UF milk) or ultrafiltered nonfat milk (UF nonfat milk) in the production of standardized cheeses and related cheese products. More specifically, this guidance is intended to advise food manufacturers of our intent to exercise enforcement discretion regarding the use and labeling of UF milk and UF nonfat milk in these cheeses, when used in addition to the dairy ingredients specified in the standards of identity in 21 CFR part 133.
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.
II. Background
Mechanical filtration technologies available for milk processing include ultrafiltration. For purposes of this guidance, we consider filtration to be a process whereby milk is passed over a series of semipermeable membranes with varying pore sizes. The portion of milk that passes through the membranes is referred to as the “permeate,” and the portion that does not pass through the membranes is referred to as the “retentate.” Ultrafiltration retains macromolecules and particles larger than about 0.001–0.02 micrometers. In dairy processing, ultrafiltration is typically used to retain all protein components of milk, including casein and whey proteins, while some of the lactose, minerals, and water soluble vitamins present in milk are lost along with water.
For purposes of this guidance, UF milk means raw or pasteurized milk that is passed over one or more semipermeable membranes to partially remove water, lactose, minerals, and water-soluble vitamins without altering the casein:whey protein ratio of the milk and resulting in a liquid product. (Additional specifications on UF milk are discussed in FDA’s 2005 proposed rule, “Cheeses and Related Cheese Products; Proposal to Permit the Use of Ultrafiltered Milk,” 70 FR 60751 (October 19, 2005).) UF nonfat milk is defined similarly, except that raw or pasteurized nonfat milk is used.
Our regulations specify the standards of identity for cheeses and related cheese products in part 133 (21 CFR part 133). The general provisions within part 133, in part, define “milk” and “nonfat milk” that may be used in the manufacture of cheeses and related cheese products. The definitions for “milk” and “nonfat milk” in § 133.3(a) and (b), respectively, list different forms of milk and nonfat milk, including concentrated, reconstituted, and dried forms, that may be used in the making of cheeses and related cheese products. Fluid or dried filtered forms of milk obtained through mechanical filtration of milk or nonfat milk are not included within these definitions. Therefore, while current regulations permit the use of concentrated, reconstituted, and dried forms of milk and nonfat milk as basic dairy ingredients (i.e., the only difference in these ingredients is the amount of water), they do not provide for the use of fluid or dried filtered milk or fluid or dried filtered nonfat milk as basic dairy ingredients in standardized cheeses and related cheese products.
Consistent with our general labeling provisions in 21 CFR 101.4, ingredients used in standardized cheeses are required to be declared by their common or usual name in descending order of predominance by weight.
III. Discussion
In the Federal Register of October 19, 2005 (70 FR 60751), we issued a proposed rule that would amend our regulations to provide for the use of fluid UF milk in the manufacture of standardized cheeses and related cheese products. We tentatively concluded that the proposed rule, if finalized, would promote honesty and fair dealing in the interest of consumers and, to the extent practicable, achieve consistency with existing international standards of identity for cheeses and related cheese products. We explained our tentative conclusion that fluid UF milk can be used in standardized cheeses while preserving the basic nature and maintaining the essential characteristics of the food, while providing for greater flexibility in cheesemaking. However, we also noted in the proposed rule that,
“[p]roviding for the use of fluid UF milk does not preclude a standardized cheese from meeting the existing requirements within the applicable individual standard(s) of identity in part 133. Rather, the use of fluid UF milk would be optional and any cheese made using fluid UF milk would have to meet all the requirements, including the physical and chemical characteristics, specified in the applicable individual standards of identity” (70 FR 60751 at 60757).
The comment period for the 2005 proposed rule was reopened on December 11, 2007 (72 FR 70251) and extended until April 11, 2008 (73 FR 7692 (Feb. 11, 2008)). However, due to competing priorities, as of August 2017, we have not completed the rulemaking.
Recently, we have become aware of issues regarding domestically produced UF milk in the international marketplace. In brief, due to recent developments in some export markets, the United States dairy industry is experiencing an oversupply and pricing challenges with domestically produced UF milk (Refs. 1 and 2). Additionally, we have received requests to exercise enforcement discretion while the rulemaking is pending, in part to mitigate the impact on U.S. companies producing UF milk (Ref. 3).
FDA believes that food standards should provide for flexibility in manufacturing procedures and ingredients, provided that the basic nature and essential characteristics of the food are preserved. Given the oversupply of UF milk and the pending rulemaking, through this guidance, we are announcing our intent to exercise enforcement discretion regarding the use of fluid UF milk and fluid UF nonfat milk in the production of standardized cheeses and related cheese products under 21 CFR part 133, in addition to the other required dairy ingredients, provided that the physical, chemical, and organoleptic properties of the cheese or cheese product are not affected.
FDA is also announcing its intent to exercise enforcement discretion with respect to the labeling of standardized cheeses and related cheese products, when, in addition to milk or nonfat milk, fluid UF milk or fluid UF nonfat milk is used as an ingredient, but is not declared in the ingredient statement, provided that milk or nonfat milk is declared in the ingredient statement. We are exercising enforcement discretion with respect to the labeling of fluid UF milk and fluid UF nonfat milk in recognition of the costs and logistics involved in label changes, although we encourage industry to identify the ingredients as “ultrafiltered milk” and “ultrafiltered nonfat milk” to the extent feasible and appropriate.
We intend to exercise enforcement discretion until we have completed a rulemaking process amending our regulations with respect to the issues covered by this guidance, or announce in the Federal Register our determination not to proceed with such a rulemaking.
IV. References
We have placed the following references on display with the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. You may see them at that location between 9 a.m. and 4 p.m., Monday through Friday. As of August 8, 2017, FDA had verified the Web site address for the references we make available as hyperlinks from the Internet copy of this guidance, but we are not responsible for any subsequent changes to Non-FDA Web site references after August 8, 2017.
- Letter from Senator Amy Klobuchar, Senator Al Franken, Representative Collin Peterson, and Representative Tim Walz, to President Donald J. Trump, accessed on the Web at https://www.klobuchar.senate.gov/public/index.cfm/2017/4/klobuchar-franken-peterson-walz-urge-administration-to-support-minnesota-dairy-farmers-through-strong-enforcement-of-our-trade-laws-with-canada.
- Congressional Research Service, “New Canadian Dairy Pricing Regime Proves Disruptive for U.S. Milk Producers,” dated April 20, 2017, accessed on the Web at https://www.everycrsreport.com/reports/IN10692.html
. - Letter from Michael D. Dykes, D.V.M., President and CEO, International Dairy Foods Association, to Stephen Ostroff, M.D., Deputy Commissioner for Foods and Veterinary Medicine, Food and Drug Administration, dated June 22, 2017.
Related Information
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2017-D-4713.
最新政策法规资讯
-
摩熵医药2026-06-17
-
摩熵医药2026-06-09
-
赛柏蓝2026-06-01
-
深蓝观2026-05-22
-
赛柏蓝2026-04-24
-
摩熵医械2026-01-28
-
摩熵医械2026-01-13
-
摩熵医械2025-12-19
-
赛柏蓝2025-12-12
-
摩熵医械2025-11-28
热门政策标签
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-10-14
-
2026-10-14
-
摩熵咨询 35 78
-
摩熵咨询 28 65
-
颁布机构:国家市场监督管理总局 2026-09-30
-
颁布机构:国家市场监督管理总局 2026-09-29
最新指导原则
-
国家药监局器审中心关于发布<人表皮生长因子受体2基因扩增检测试剂(荧光原位杂交法)注册审查指导原则(2026年修订版)>等2项注册审查指导原则的通告(2026年第28号)
2026-10-13
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
国家药监局器审中心关于发布有源植入式医疗器械电池注册审查指导原则的通告(2026年第27号)
2026-10-08
-
国家药监局器审中心关于发布腹腔内窥镜手术系统注册审查指导原则 第5部分:患者模型试验研究>的通告(2026年第26号)
2026-09-28
-
国家药监局综合司公开征求<医疗器械生产质量管理规范无菌医疗器械检查指导原则(征求意见稿)>等意见
2026-09-24
-
关于公开征求ich<e14/s7b:问答:致qt/qtc 间期延长及潜在致心律失常作用的临床和非临床评价问答>指导原则问答文件实施建议和中文翻译稿意见的通知
2026-09-24
-
国家药监局药审中心关于发布<药物临床试验计算机化系统和电子数据指导原则>的通告
2026-09-22
-
国家药监局药审中心关于发布<化学仿制药滴眼剂研究技术指导原则>和<化学仿制药特殊滴眼剂研究技术指导原则>的通告
2026-09-02
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
国家卫生健康委办公厅关于印发医疗机构卒中中心建设与管理指导原则(2026年版)的通知
2026-07-28
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-10-15
-
2026-10-15
-
2026-10-15
-
摩熵咨询 33 34
-
摩熵咨询 20 8
-
摩熵咨询 20 12
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
同部门最新指导原则
-
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
2024-11-15
-
Guidance for Industry: FDA's Voluntary Qualified Importer Program
2024-11-14
-
CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24)
2024-11-01
-
Study Data Technical Conformance Guide - Technical Specifications Document
2024-10-31
-
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
2024-10-30
-
CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients
2024-10-24
-
Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination
2024-10-22
-
Drug Interaction Information in Human Prescription Drug and Biological Product Labeling
2024-10-21
-
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA
2024-10-17
-
Postoperative Nausea and Vomiting: Developing Drugs for Prevention
2024-10-17
-
Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method
2024-10-17
-
Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry
2024-10-17
-
Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry
2024-10-17
-
Requests for Reconsideration at the Division Level Under GDUFA
2024-10-16
-
CVM GFI #284 Using Relative Supersaturation to Support “Urinary Tract Health” Claims for Adult Maintenance Cat Food
2024-10-15
同地域最新指导原则
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
-
opioid analgesic drugs: considerations for benefit-risk assessment framework(阿片类镇痛药:效益-风险评估框架的考量)
2026-05-13
-
development of non-opioid analgesics for acute pain(急性疼痛的非阿片类镇痛药开发)
2026-05-13
-
development of local anesthetic drug products with prolonged duration of effect(延长作用时间的局部麻醉药品的开发)
2026-05-13
-
stimulant use disorders: developing drugs for treatment(兴奋剂使用障碍:治疗药物的开发)
2026-05-13
-
development of non-opioid analgesics for chronic pain(慢性疼痛非阿片类镇痛药的开发)
2026-05-13
-
pulmonary tuberculosis: developing drugs for treatment(肺结核:治疗药物的开发)
2026-05-08
-
clostridioides difficile infection: developing drugs for treatment, reduction of recurrence, and prevention(艰难梭菌感染:用于治疗、减少复发及预防的药物开发)
2026-05-08
-
enforcement priorities for certain new tobacco products marketed without premarket authorization(未经上市前授权销售的某些新烟草产品的执法重点)
2026-05-08

